Page 254 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 254
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0775 FINAL EVALUATION OF 955 HCV PATIENTS TREATED
WITH 12 WEEK REGIMENS CONTAINING SOFOSBUVIR
+/- SIMEPREVIR IN THE TRIO NETWORK: ACADEMIC
AND COMMUNITY TREATMENT OF A REAL-WORLD,
HETEROGENEOUS POPULATION
Douglas Dieterich*, Bruce Bacon, Steven Flamm, Kris Kowdley,
Scott Milligan, Naoky Tsai, Zobair Younossi, Eric Lawitz,
The United States
P0776 EFFICACY OF 12 OR 18 WEEKS OF GRAZOPREVIR PLUS
ELBASVIR WITH RIBAVIRIN IN TREATMENT-NAIVE,
NONCIRRHOTIC HCV GENOTYPE 3–INFECTED PATIENTS
Edward Gane*, Ronald Nahass, Velimir Luketic, Peggy Hwang,
Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber, New Zealand
P0777 SOFOSBUVIR-BASED TREATMENT UNDER REAL LIFE
CONDITIONS IN GERMANY (THE SOFGER TRIAL)
ePOSTERS Peter Buggisch*, Christoph Sarrazin, Stefan Mauss, Holger Hinrichsen,
Karl-Georg Simon, Johannes Vermehren, Dietrich Hueppe, Jörg Petersen,
Germany
P0778 THE EFFECT OF HCV ANTIVIRAL THERAPY ON FIBROSIS
PROGRESSION
Mei Lu, Jia Li, Loralee B. Rupp, Scott D. Holmberg, Anne C. Moorman,
Philip R. Spradling, Eyasu Tehale, Fujie Xu, Joseph A. Boscarino,
Vinutha Vijayadeva, Mark A. Schmidt, Lois E. Lamerato, Stuart Gordon*,
The United States
P0779 LEDIPASVIR/SOFOSBUVIR WITH RIBAVIRIN FOR THE
TREATMENT OF FIBROSING CHOLESTATIC HEPATITIS C
AFTER LIVER TRANSPLANTATION
Xavier Forns*, David Mutimer, Michael Manns, K. R. Reddy,
Gregory T. Everson, Steven L. Flamm, Jill Denning, Sarah Arterburn,
Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison,
Nezam Afdhal, Michael Charlton, Didier Samuel, Edward Gane, Spain
P0780 DEEP SEQUENCING ANALYSES IN HCV GENOTYPE
1-INFECTED PATIENTS TREATED WITH SIMEPREVIR PLUS
SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN THE COSMOS
STUDY
Bart Fevery*, Kim Thys, Elizabeth Van Rossem, Thierry Verbinnen,
Gaston Picchio, Jeroen Aerssens, Sandra De Meyer, Maria Beumont,
Darryl Kurland, Oliver Lenz, Belgium
254 The International Liver Congress™ 2015 • ILC Programme
P0775 FINAL EVALUATION OF 955 HCV PATIENTS TREATED
WITH 12 WEEK REGIMENS CONTAINING SOFOSBUVIR
+/- SIMEPREVIR IN THE TRIO NETWORK: ACADEMIC
AND COMMUNITY TREATMENT OF A REAL-WORLD,
HETEROGENEOUS POPULATION
Douglas Dieterich*, Bruce Bacon, Steven Flamm, Kris Kowdley,
Scott Milligan, Naoky Tsai, Zobair Younossi, Eric Lawitz,
The United States
P0776 EFFICACY OF 12 OR 18 WEEKS OF GRAZOPREVIR PLUS
ELBASVIR WITH RIBAVIRIN IN TREATMENT-NAIVE,
NONCIRRHOTIC HCV GENOTYPE 3–INFECTED PATIENTS
Edward Gane*, Ronald Nahass, Velimir Luketic, Peggy Hwang,
Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber, New Zealand
P0777 SOFOSBUVIR-BASED TREATMENT UNDER REAL LIFE
CONDITIONS IN GERMANY (THE SOFGER TRIAL)
ePOSTERS Peter Buggisch*, Christoph Sarrazin, Stefan Mauss, Holger Hinrichsen,
Karl-Georg Simon, Johannes Vermehren, Dietrich Hueppe, Jörg Petersen,
Germany
P0778 THE EFFECT OF HCV ANTIVIRAL THERAPY ON FIBROSIS
PROGRESSION
Mei Lu, Jia Li, Loralee B. Rupp, Scott D. Holmberg, Anne C. Moorman,
Philip R. Spradling, Eyasu Tehale, Fujie Xu, Joseph A. Boscarino,
Vinutha Vijayadeva, Mark A. Schmidt, Lois E. Lamerato, Stuart Gordon*,
The United States
P0779 LEDIPASVIR/SOFOSBUVIR WITH RIBAVIRIN FOR THE
TREATMENT OF FIBROSING CHOLESTATIC HEPATITIS C
AFTER LIVER TRANSPLANTATION
Xavier Forns*, David Mutimer, Michael Manns, K. R. Reddy,
Gregory T. Everson, Steven L. Flamm, Jill Denning, Sarah Arterburn,
Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison,
Nezam Afdhal, Michael Charlton, Didier Samuel, Edward Gane, Spain
P0780 DEEP SEQUENCING ANALYSES IN HCV GENOTYPE
1-INFECTED PATIENTS TREATED WITH SIMEPREVIR PLUS
SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN THE COSMOS
STUDY
Bart Fevery*, Kim Thys, Elizabeth Van Rossem, Thierry Verbinnen,
Gaston Picchio, Jeroen Aerssens, Sandra De Meyer, Maria Beumont,
Darryl Kurland, Oliver Lenz, Belgium
254 The International Liver Congress™ 2015 • ILC Programme
